• Loading stock data...
Est. 2004

LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

Monday 04/23/2018
SMALL CAP MARKET NEWS

We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.


LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

Abattis Bioceuticals

  • 10:34 AM

    VANCOUVER, British Columbia, March 13, 2018 /PRNewswire/ — Abattis Bioceuticals Corp. (the “Company” or “Abattis “) (CSE: ATT) (OTC: ATTBF) is pleased to announce it has entered into a non-binding letter of intent (the “LOI“) with Canadian Artesian Ice Ltd. (“Canadian Artesian“) to provide Canadian Artesian with, among other things, THC- and pesticide-free cannabidiol (“CBD“) isolate, research and development services, nanoencapsulation and nanoemulsification services, analytical and regulatory services and access to Abattis’s distribution and marketing channels to support the development, scalability and commercialization of

    Read more
  • 3:32 PM

    LEXINGTON, MA— XBIO, (Marketwired – February 12, 2016) – Xenetic Biosciences, Inc. (OTCQB: XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics (“Xenetic”) announced today that OPKO Health, Inc. (NYSE: OPK) has acquired an approximate 6.3% interest in Xenetic. Commenting on the investment in Xenetic, Dr. Phillip Frost, CEO and Chairman of OPKO Health, Inc., stated, “Xenetic has many novel technologies that address unmet needs in various orphan cancer indications, and we believe the science

    Read more
  • 7:07 PM

    LEXINGTON, Mass., July 08, 2015 (GLOBE NEWSWIRE) — Xenetic Biosciences, Inc. (“Xenetic” or the “Company”) (OTCQB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel orphan oncology therapeutics, today announced that it has completed a $3,000,000 bridge note financing. The financing was concluded with OJSC Pharmsynthez (“Pharmsynthez”), a collaborative partner of Xenetic and an affiliate of Xenetic’s largest shareholder SynBio LLC (“Synbio”) and was arranged directly between the managements of Xenetic and Pharmsynthez on a commission free basis.

    Read more
  • 9:47 PM

    CHWE XBIO & PPJE  More Info @  Web Site:  www.OTCMarkets.com  Thursday, June 19th   CHWE – UP 5,900% Note:  Crazy volume…no news…only 43 Mil shares out   XBIO –  UP 183% OTOW -UP 63% ITGC –  UP 36%    SUB PENNY GAINERS – PPJE +150%, MSPC +66%,  TREP +49%, DNAX +43% and RITE +33%      Stocks that took a tumble today- ASKE down 50% CNAB down 32%  ECAU down 30% 

    Read more
Public Wire Banner